Search | Page 15 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Eltrombopag in aplastic anemia

    ... a potential therapy in case of stem cell depletion in refractory aplastic anemia. Eltrombopag was used for 43 aplastic anemia patients who were refractory to IST at National Institutes of Health (NIH), improving blood ...

    Research Review last updated 05/02/2016 - 9:13am.

  2. AML Therapy With Irradiated Allogeneic Cells

    ... Histologically proven non-M3 AML: Refractory /relapsed AML OR Initial diagnosis of AML in patient >= 60 ...

    Clinical Trial last updated 06/13/2016 - 3:14pm.

  3. Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

    ... confirmed are eligible Acute leukemia, primary refractory or beyond CR1 High risk acute myeloid leukemia in CR1 with ...

    Clinical Trial last updated 05/09/2016 - 3:58pm.

  4. Preventing Stem Cell Transplant Complications With a Blood Separator Machine

    ... syndromes (MDS): any of these categories - refractory anemia with transfusion dependence, refractory anemia with ANC< 500/microL, refractory anemia with excess of ...

    Clinical Trial last updated 05/23/2016 - 10:57am.

  5. LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)

    ... drug combination when given to patients with relapsed or refractory AML or HRMDS will also be studied. ...

    Clinical Trial last updated 04/28/2016 - 1:47pm.

  6. Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

    ... combination has been used in the treatment of relapsed/ refractory multiple myeloma and has been previously investigated in the ...

    Clinical Trial last updated 04/28/2016 - 10:20am.

  7. A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

    ... pharmacokinetics of TEN-010 in patients with relapsed/ refractory acute myeloid leukemia (RR-AML) and hypomethylating agent ... cohorts of three or more patients with RR-AML or HMA-refractory MDS will be treated at escalating doses until a maximum tolerated ...

    Clinical Trial last updated 04/28/2016 - 10:02am.

  8. New York Blood Center National Cord Blood Program

    ... marrow donor. Most patients are those with high risk of refractory leukemia, lymphoma, myelodysplasia, severe aplastic anemia ...

    Clinical Trial last updated 04/27/2016 - 3:36pm.

  9. A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)

    ... (IV) infusion, in subjects with relapsed and/or primary refractory AML and high-risk MDS. The study will explore escalating doses ...

    Clinical Trial last updated 04/27/2016 - 1:31pm.

  10. A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

    ... hypomethylating agents(s) (HMAs) or have relapsed or are refractory to prior HMA therapy. The primary objectives of this study are ...

    Clinical Trial last updated 04/27/2016 - 9:57am.